Point72 Asset Management
CRNX icon

Point72 Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Point72 Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,337,034
Closed -$109M – 3886
2025
Q4 		$109M Buy
2,337,034
+333,701
+17% +$14.9M 0.12% 161
2025
Q3 		$83.4M Buy
2,003,333
+5,172
+0.3% +$165K 0.14% 156
2025
Q2 		$57.5M Buy
1,998,161
+1,219,763
+157% +$37.7M 0.11% 217
2025
Q1 		$26.1M Sell
778,398
-2,010,541
-72% -$75.1M 0.06% 376
2024
Q4 		$143M Buy
2,788,939
+488,296
+21% +$27.3M 0.31% 62
2024
Q3 		$118M Sell
2,300,643
-480,213
-17% -$24.8M 0.3% 64
2024
Q2 		$125M Sell
2,780,856
-2,168,630
-44% -$100M 0.33% 69
2024
Q1 		$232M Buy
4,949,486
+1,532,586
+45% +$60M 0.56% 24
2023
Q4 		$122M Sell
3,416,900
-808,400
-19% -$24.8M 0.29% 63
2023
Q3 		$126M Buy
+4,225,300
New +$87.1M 0.37% 47
2023
Q2 		– Sell
-226,400
Closed -$3.64M – 2263
2023
Q1 		$3.64M Sell
226,400
-1,134,600
-83% -$21M 0.01% 851
2022
Q4 		$24.9M Buy
1,361,000
+50,800
+4% +$895K 0.08% 284
2022
Q3 		$25.7M Sell
1,310,200
-22,600
-2% -$461K 0.1% 263
2022
Q2 		$24.9M Buy
1,332,800
+126,462
+10% +$2.52M 0.1% 261
2022
Q1 		$26.5M Buy
1,206,338
+101,862
+9% +$2.06M 0.11% 257
2021
Q4 		$31.4M Buy
1,104,476
+654,676
+146% +$16.1M 0.13% 229
2021
Q3 		$9.47M Sell
449,800
-258,333
-36% -$5.4M 0.04% 504
2021
Q2 		$13.3M Sell
708,133
-566,867
-44% -$9.96M 0.06% 384
2021
Q1 		$19.5M Buy
1,275,000
+49,997
+4% +$775K 0.09% 272
2020
Q4 		$17.3M Buy
1,225,003
+713,015
+139% +$9.93M 0.08% 310
2020
Q3 		$8.02M Buy
511,988
+117,156
+30% +$1.79M 0.04% 458
2020
Q2 		$6.92M Buy
+394,832
New +$6.73M 0.05% 416
2020
Q1 		– Sell
-33,865
Closed -$850K – 821
2019
Q4 		$850K Sell
33,865
-98,135
-74% -$1.87M ﹤0.01% 733
2019
Q3 		$1.99M Buy
+132,000
New +$2.57M 0.01% 593

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management's CRNX Position: Q1 2026 in Review

Point72 Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 2,337,034 shares — an estimated $109M sold.

Point72 Asset Management first reported a position in CRNX in Q3 2019 and held it in 24 quarters. The position peaked at $232M in Q1 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Point72 Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 2,337,034 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $109M.
  • Point72 Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2019 and held it in 24 quarters.
  • Point72 Asset Management's Crinetics Pharmaceuticals position peaked at $232M in Q1 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.